A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel‑Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome
Phase of Trial: Phase II/III
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Postpoliomyelitis syndrome
- Focus Therapeutic Use
- Acronyms FORCE
- Sponsors Grifols
- 31 Aug 2018 Biomarkers information updated
- 15 Jan 2018 Planned End Date changed from 1 Sep 2020 to 1 Jun 2021.
- 15 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2021.